Valproic acid monotherapy in pregnancy and major congenital malformations
Copyright 2010 Massachusetts Medical Society..
BACKGROUND: The use of valproic acid in the first trimester of pregnancy is associated with an increased risk of spina bifida, but data on the risks of other congenital malformations are limited.
METHODS: We first combined data from eight published cohort studies (1565 pregnancies in which the women were exposed to valproic acid, among which 118 major malformations were observed) and identified 14 malformations that were significantly more common among the offspring of women who had received valproic acid during the first trimester. We then assessed the associations between use of valproic acid during the first trimester and these 14 malformations by performing a case-control study with the use of the European Surveillance of Congenital Anomalies (EUROCAT) antiepileptic-study database, which is derived from population-based congenital-anomaly registries. Registrations (i.e., pregnancy outcomes with malformations included in EUROCAT) with any of these 14 malformations were compared with two control groups, one consisting of infants with malformations not previously linked to valproic acid use (control group 1), and one consisting of infants with chromosomal abnormalities (control group 2). The data set included 98,075 live births, stillbirths, or terminations with malformations among 3.8 million births in 14 European countries from 1995 through 2005.
RESULTS: Exposure to valproic acid monotherapy was recorded for a total of 180 registrations, with 122 registrations in the case group, 45 in control group 1, and 13 in control group 2. As compared with no use of an antiepileptic drug during the first trimester (control group 1), use of valproic acid monotherapy was associated with significantly increased risks for 6 of the 14 malformations under consideration; the adjusted odds ratios were as follows: spina bifida, 12.7 (95% confidence interval [CI], 7.7 to 20.7); atrial septal defect, 2.5 (95% CI, 1.4 to 4.4); cleft palate, 5.2 (95% CI, 2.8 to 9.9); hypospadias, 4.8 (95% CI, 2.9 to 8.1); polydactyly, 2.2 (95% CI, 1.0 to 4.5); and craniosynostosis, 6.8 (95% CI, 1.8 to 18.8). Results for exposure to valproic acid were similar to results for exposure to other antiepileptic drugs.
CONCLUSIONS: The use of valproic acid monotherapy in the first trimester was associated with significantly increased risks of several congenital malformations, as compared with no use of antiepileptic drugs or with use of other antiepileptic drugs.
| Errataetall: |
CommentIn: N Engl J Med. 2010 Oct 28;363(18):1771; author reply 1771-2. - PMID 20979483 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2010 |
|---|---|
| Erschienen: |
2010 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:362 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 362(2010), 23 vom: 10. Juni, Seite 2185-93 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jentink, Janneke [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
614OI1Z5WI |
|---|
| Anmerkungen: |
Date Completed 22.06.2010 Date Revised 08.04.2022 published: Print CommentIn: N Engl J Med. 2010 Oct 28;363(18):1771; author reply 1771-2. - PMID 20979483 Citation Status MEDLINE |
|---|
| doi: |
10.1056/NEJMoa0907328 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM198916744 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM198916744 | ||
| 003 | DE-627 | ||
| 005 | 20231223213629.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMoa0907328 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0663.xml |
| 035 | |a (DE-627)NLM198916744 | ||
| 035 | |a (NLM)20558369 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jentink, Janneke |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Valproic acid monotherapy in pregnancy and major congenital malformations |
| 264 | 1 | |c 2010 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.06.2010 | ||
| 500 | |a Date Revised 08.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: N Engl J Med. 2010 Oct 28;363(18):1771; author reply 1771-2. - PMID 20979483 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright 2010 Massachusetts Medical Society. | ||
| 520 | |a BACKGROUND: The use of valproic acid in the first trimester of pregnancy is associated with an increased risk of spina bifida, but data on the risks of other congenital malformations are limited | ||
| 520 | |a METHODS: We first combined data from eight published cohort studies (1565 pregnancies in which the women were exposed to valproic acid, among which 118 major malformations were observed) and identified 14 malformations that were significantly more common among the offspring of women who had received valproic acid during the first trimester. We then assessed the associations between use of valproic acid during the first trimester and these 14 malformations by performing a case-control study with the use of the European Surveillance of Congenital Anomalies (EUROCAT) antiepileptic-study database, which is derived from population-based congenital-anomaly registries. Registrations (i.e., pregnancy outcomes with malformations included in EUROCAT) with any of these 14 malformations were compared with two control groups, one consisting of infants with malformations not previously linked to valproic acid use (control group 1), and one consisting of infants with chromosomal abnormalities (control group 2). The data set included 98,075 live births, stillbirths, or terminations with malformations among 3.8 million births in 14 European countries from 1995 through 2005 | ||
| 520 | |a RESULTS: Exposure to valproic acid monotherapy was recorded for a total of 180 registrations, with 122 registrations in the case group, 45 in control group 1, and 13 in control group 2. As compared with no use of an antiepileptic drug during the first trimester (control group 1), use of valproic acid monotherapy was associated with significantly increased risks for 6 of the 14 malformations under consideration; the adjusted odds ratios were as follows: spina bifida, 12.7 (95% confidence interval [CI], 7.7 to 20.7); atrial septal defect, 2.5 (95% CI, 1.4 to 4.4); cleft palate, 5.2 (95% CI, 2.8 to 9.9); hypospadias, 4.8 (95% CI, 2.9 to 8.1); polydactyly, 2.2 (95% CI, 1.0 to 4.5); and craniosynostosis, 6.8 (95% CI, 1.8 to 18.8). Results for exposure to valproic acid were similar to results for exposure to other antiepileptic drugs | ||
| 520 | |a CONCLUSIONS: The use of valproic acid monotherapy in the first trimester was associated with significantly increased risks of several congenital malformations, as compared with no use of antiepileptic drugs or with use of other antiepileptic drugs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Anticonvulsants |2 NLM | |
| 650 | 7 | |a Valproic Acid |2 NLM | |
| 650 | 7 | |a 614OI1Z5WI |2 NLM | |
| 700 | 1 | |a Loane, Maria A |e verfasserin |4 aut | |
| 700 | 1 | |a Dolk, Helen |e verfasserin |4 aut | |
| 700 | 1 | |a Barisic, Ingeborg |e verfasserin |4 aut | |
| 700 | 1 | |a Garne, Ester |e verfasserin |4 aut | |
| 700 | 1 | |a Morris, Joan K |e verfasserin |4 aut | |
| 700 | 1 | |a de Jong-van den Berg, Lolkje T W |e verfasserin |4 aut | |
| 700 | 0 | |a EUROCAT Antiepileptic Study Working Group |e verfasserin |4 aut | |
| 700 | 1 | |a Verellen-Dumoulin, C |e investigator |4 oth | |
| 700 | 1 | |a Nelen, V |e investigator |4 oth | |
| 700 | 1 | |a Barisic, I |e investigator |4 oth | |
| 700 | 1 | |a Garne, E |e investigator |4 oth | |
| 700 | 1 | |a Khoshnood, B |e investigator |4 oth | |
| 700 | 1 | |a Doray, B |e investigator |4 oth | |
| 700 | 1 | |a Poetzsch, S |e investigator |4 oth | |
| 700 | 1 | |a Wiesel, A |e investigator |4 oth | |
| 700 | 1 | |a O'Mahony, M |e investigator |4 oth | |
| 700 | 1 | |a Pierini, A |e investigator |4 oth | |
| 700 | 1 | |a Rivieri, F |e investigator |4 oth | |
| 700 | 1 | |a Gatt, M |e investigator |4 oth | |
| 700 | 1 | |a Bakker, M |e investigator |4 oth | |
| 700 | 1 | |a Melve, K |e investigator |4 oth | |
| 700 | 1 | |a Latos-Bielenska, A |e investigator |4 oth | |
| 700 | 1 | |a Mejnartowicz, J P |e investigator |4 oth | |
| 700 | 1 | |a Portillo, I |e investigator |4 oth | |
| 700 | 1 | |a Addor, M-C |e investigator |4 oth | |
| 700 | 1 | |a Tucker, D |e investigator |4 oth | |
| 700 | 1 | |a Wellesley, D |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d 1945 |g 362(2010), 23 vom: 10. Juni, Seite 2185-93 |w (DE-627)NLM000008184 |x 1533-4406 |7 nnns |
| 773 | 1 | 8 | |g volume:362 |g year:2010 |g number:23 |g day:10 |g month:06 |g pages:2185-93 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/NEJMoa0907328 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 362 |j 2010 |e 23 |b 10 |c 06 |h 2185-93 | ||